Oxford BioMedica plc (GB:OXB)
LSE:OXB
Want to see GB:OXB full AI Analyst Report?
Top Page
Oxford BioMedica
(LSE:OXB)
Select Model
Select Model
Rating:43Neutral
Price Target:
615.00 p
â–²(6.96% Upside)
Action:ReiteratedDate:03/27/26
The score is held back primarily by weak financial performance (still loss-making with negative operating/free cash flow despite improvement) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Durable CDMO business model
Specialized CDMO services for viral vectors create durable, contract-driven revenue streams tied to clients' multi-stage development and commercial needs. GMP manufacturing and process know‑how raise switching costs and support repeat business, lending structural revenue visibility over months.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flow means the business still consumes cash to run and invest. Reliance on external funding to bridge shortfalls constrains strategic options, capital expenditure and hiring, and presents a durable liquidity risk if financing conditions tighten over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Durable CDMO business model
Specialized CDMO services for viral vectors create durable, contract-driven revenue streams tied to clients' multi-stage development and commercial needs. GMP manufacturing and process know‑how raise switching costs and support repeat business, lending structural revenue visibility over months.
Read all positive factors
Oxford BioMedica (OXB) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£741.12M
Dividend YieldN/A
Average Volume (3M)323.90K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth31.01%
EPS Growth31.72%
CountryUK
Employees850
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding120,900,850
10 Day Avg. Volume339,869
30 Day Avg. Volume323,903
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)7.56
Price to Sales (P/S)4.09
P/FCF Ratio-67.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£982.33Price Target Upside70.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.09
Revenue Forecast (FY)£229.30M
Oxford BioMedica Business Overview & Revenue Model
Company Description
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector...
How the Company Makes Money
Oxford BioMedica makes money primarily by providing contract development and manufacturing services (CDMO) for viral vectors used by biopharmaceutical partners. Key revenue streams typically include: (1) Process and analytical development services...
Oxford BioMedica Earnings Call Summary
Earnings Call Date:Apr 09, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Sep 23, 2026
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with significant revenue growth, increased client orders, operational efficiency improvements, and strategic expansions. However, challenges such as the operating EBITDA loss and negative working capital movement were noted.Positive Updates
Impressive Organic Revenue Growth
The company achieved an organic revenue growth of 81% and total revenues increased by 44% to GBP128.8 million in 2024.
Negative Updates
Operating EBITDA Loss
Despite improvements, the company reported an operating EBITDA loss of GBP15.3 million for 2024.
Read all updates
Q4-2024 Updates
Positive
Negative
Impressive Organic Revenue Growth
The company achieved an organic revenue growth of 81% and total revenues increased by 44% to GBP128.8 million in 2024.
Read all positive updates
Company Guidance
In the 2024 analyst briefing, OXB reported strong financial performance with an impressive organic revenue growth of 81%, resulting in total revenues of GBP128.8 million, a 44% increase from the previous year. Their pipeline expanded by 30% to $570 million, and customer orders grew by 35% to GBP186 million. The company achieved an operating EBITDA profit of GBP5 million in the second half of the year, narrowing their annual operating EBITDA loss to GBP15.3 million, a significant improvement from 2023's GBP52.8 million loss. For 2025, OXB expects revenues between GBP160 million and GBP170 million, with over 80% of this already covered by existing orders. The company plans to achieve a low single-digit million operating EBITDA profit, with a focus on continued margin expansion driven by operational efficiencies and strong commercial momentum.Oxford BioMedica Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 168.74M | 128.80M | 89.54M | 139.99M | 142.80M |
| Gross Profit | 65.98M | 53.02M | 39.73M | 69.18M | 82.64M |
| EBITDA | -33.54M | -14.33M | -148.62M | -10.80M | 33.22M |
| Net Income | -30.13M | -43.19M | -157.49M | -39.16M | 19.01M |
Balance Sheet | |||||
| Total Assets | 325.72M | 231.64M | 252.34M | 460.18M | 237.23M |
| Cash, Cash Equivalents and Short-Term Investments | 96.88M | 60.65M | 103.72M | 141.31M | 109.02M |
| Total Debt | 106.64M | 108.76M | 111.46M | 114.28M | 9.34M |
| Total Liabilities | 234.37M | 171.16M | 174.51M | 223.99M | 49.89M |
| Stockholders Equity | 91.35M | 57.05M | 74.01M | 204.65M | 187.34M |
Cash Flow | |||||
| Free Cash Flow | -10.21M | -58.12M | -38.35M | -28.91M | 15.99M |
| Operating Cash Flow | -5.45M | -50.63M | -28.52M | -12.62M | 25.45M |
| Investing Cash Flow | -8.10M | 5.63M | 2.81M | -56.46M | -9.46M |
| Financing Cash Flow | 50.59M | 2.91M | -12.70M | 98.62M | 46.21M |
Oxford BioMedica Technical Analysis
Positive
575.00
Price Trends
661.48
Negative
685.29
Negative
611.14
Positive
Market Momentum
-9.89
Negative
57.68
Neutral
81.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OXB, the sentiment is Positive. The current price of 575 is below the 20-day moving average (MA) of 586.55, below the 50-day MA of 661.48, and below the 200-day MA of 611.14, indicating a neutral trend. The MACD of -9.89 indicates Negative momentum. The RSI at 57.68 is Neutral, neither overbought nor oversold. The STOCH value of 81.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:OXB.
Oxford BioMedica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £132.32M | -4.45 | 90.29% | ― | ― | 69.01% | |
55 Neutral | £298.43M | -2.25 | 12.82% | ― | 1231.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £51.79M | -0.27 | -3931.14% | ― | ― | -28.54% | |
46 Neutral | £24.92M | 45.77 | -197.54% | ― | 3.31% | 21.91% | |
43 Neutral | £741.12M | -22.92 | -48.56% | ― | 31.01% | 31.72% | |
42 Neutral | £324.99M | -1.74 | -361.23% | ― | ― | ― |
* Healthcare Sector Average
GB:OXB
Oxford BioMedica
613.00
309.00
101.64%
GB:AVCT
Avacta Group plc
74.30
41.80
128.62%
GB:PRTC
PureTech Health
122.60
-2.20
-1.76%
GB:SCLP
Scancell Holdings
12.75
1.25
10.87%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
806.00
623.75
342.25%
GB:AREC
Arecor Therapeutics PLC
66.00
28.00
73.68%
Oxford BioMedica Corporate Events
Business Operations and StrategyProduct-Related Announcements
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development
Positive
Apr 13, 2026
Oxford Biomedica has introduced a new fast-track development and manufacturing service for lentiviral and adeno-associated viral vectors, aimed at biotechs facing tight timelines and funding constraints. Using its inAAVate and LentiVector platform...
Business Operations and StrategyExecutive/Board Changes
Oxford Biomedica Reinstates and Grants New Performance‑Linked Share Awards to Leadership
Positive
Apr 8, 2026
Oxford Biomedica has granted nil‑cost share options under its 2024 Long Term Incentive Plan and 2024 Deferred Bonus Plan to senior executives and key managers, including CEO Frank Mathias and CFO Lucinda Crabtree. The awards, which cover LTI...
Regulatory Filings and Compliance
Oxford Biomedica Confirms Updated Total Voting Rights
Neutral
Apr 1, 2026
Oxford Biomedica has confirmed that its issued share capital at the close of business on 31 March 2026 comprised 120,900,850 ordinary shares, with none held in treasury. As a result, the company’s total number of voting rights is 120,900,850...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role
Positive
Mar 30, 2026
Oxford Biomedica has notified shareholders that its 2026 Annual General Meeting will be held on 7 May 2026 at the company’s Oxford headquarters, with the AGM notice and the 2025 annual report and accounts now dispatched and made available on...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook
Positive
Mar 26, 2026
Oxford BioMedica reported a strong 2025 performance, with constant-currency revenue up 33% to £170.9 million and a return to positive Operating EBITDA, underpinned by growth in manufacturing, development and procurement services. Profitabilit...
Business Operations and Strategy
Oxford Biomedica licenses viral vector platforms to Australian CDMO VVMF
Positive
Mar 18, 2026
Oxford Biomedica has signed a five-year licensing and option agreement with Viral Vector Manufacturing Facility, Australia’s first dedicated commercial viral vector CDMO, granting it a worldwide, non-exclusive licence to OXB’s inAAVate...
Business Operations and StrategyDelistings and Listing Changes
Oxford Biomedica Adds Incentive Scheme Shares to London Listing
Neutral
Mar 9, 2026
Oxford Biomedica has admitted 92,381 new ordinary shares of 50p each to trading on the London Stock Exchange’s Main Market following allocations under its long-term incentive, sharesave and employee share option schemes. The new shares are f...
Business Operations and StrategyDelistings and Listing Changes
Oxford Biomedica Seeks LSE Admission for 92,381 New Incentive Shares
Neutral
Mar 4, 2026
Oxford Biomedica has applied to the London Stock Exchange for the admission to trading of 92,381 new ordinary shares, issued under its long-term incentive, sharesave and employee share option schemes. The new shares, expected to be admitted on 9 M...
Business Operations and StrategyFinancial Disclosures
Oxford Biomedica sets Capital Markets Day and tightens investor outreach calendar
Positive
Mar 3, 2026
Oxford Biomedica has set 2 June 2026 for its Capital Markets Day at the London Stock Exchange Group’s headquarters, signalling an effort to deepen engagement with investors around its cell and gene therapy CDMO strategy. The company will pro...
Regulatory Filings and Compliance
Oxford Biomedica Confirms Total Voting Rights at 120.9 Million Shares
Neutral
Mar 2, 2026
Oxford Biomedica, the Oxford-based cell and gene therapy CDMO, reported that its issued share capital at 28 February 2026 comprised 120,873,439 ordinary shares with no shares held in treasury. This figure sets the company’s total voting righ...
Business Operations and StrategyM&A Transactions
Oxford Biomedica rejects EQT approaches as suitor walks away
Neutral
Feb 25, 2026
Oxford Biomedica has rejected a series of takeover proposals from private equity group EQT, which has now formally ruled out making an offer for the company under UK takeover rules. The board, having consulted key shareholders, unanimously conclud...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Oxford Biomedica hits top-end 2025 guidance and turns EBITDA positive
Positive
Feb 24, 2026
Oxford Biomedica reported that 2025 revenues are expected to rise around 30% to £166-169 million, placing the group at the top end of guidance and marking an almost 90% increase since 2023 as it executes its pure-play CDMO strategy. The compa...
Business Operations and StrategyM&A Transactions
Oxford Biomedica Wins More Time for EQT Takeover Decision
Neutral
Feb 11, 2026
Oxford Biomedica has confirmed that preliminary talks are continuing with EQT over a possible all-cash takeover, after the private equity firm’s unsolicited approach for the entire issued and to-be-issued share capital last month. The U.K. T...
Business Operations and StrategyFinancial Disclosures
Oxford Biomedica seals multi-year CAR-T vector supply deal with Bristol Myers Squibb
Positive
Feb 4, 2026
Oxford Biomedica has expanded its long-standing relationship with Bristol Myers Squibb by signing a new multi-year commercial supply agreement to manufacture lentiviral vectors for BMS’s CAR-T cell therapy programmes. Under the deal, which r...
Regulatory Filings and Compliance
Oxford Biomedica Confirms Total Voting Rights at 120.8 Million Shares
Neutral
Feb 2, 2026
Oxford Biomedica has confirmed that its issued share capital as of 31 January 2026 comprised 120,833,190 ordinary shares, with no shares held in treasury, establishing the same figure as the total number of voting rights in the company. This discl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.